Rene In t Zandt
Overview
Explore the profile of Rene In t Zandt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
950
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kritsilis M, Vanherle L, Rosenholm M, In t Zandt R, Yao Y, Swanberg K, et al.
Brain
. 2024 Dec;
148(3):985-1000.
PMID: 39693238
Heart failure is associated with progressive reduction in cerebral blood flow and neurodegenerative changes leading to cognitive decline. The glymphatic system is crucial for the brain's waste removal, and its...
2.
Boswinkel M, Raave R, Veltien A, Scheenen T, Fransen Petterson N, In t Zandt R, et al.
Front Nucl Med
. 2024 Oct;
3:1306251.
PMID: 39355041
Objective: Accurate imaging biomarkers that indicate disease progression at an early stage are highly important to enable timely mitigation of symptoms in progressive lung disease. In this context, reproducible experimental...
3.
In t Zandt R, Mahmutovic Persson I, Tibiletti M, von Wachenfeldt K, Parker G, Olsson L
PLoS One
. 2024 Sep;
19(9):e0310643.
PMID: 39331604
Identifying biomarkers in fibrotic lung disease is key for early anti-fibrotic intervention. Dynamic contrast-enhanced (DCE) MRI offers valuable perfusion-related insights in fibrosis but adapting human MRI methods to rodents poses...
4.
Engstedt J, In t Zandt R, Barauskas J, Kocherbitov V
Colloids Surf B Biointerfaces
. 2024 May;
239:113955.
PMID: 38754200
Lipid-based drug delivery systems offer the potential to enhance bioavailability, reduce dosing frequency, and improve patient adherence. In aqueous environment, initially dry lipid depots take up water and form liquid...
5.
Mahmutovic Persson I, Fransen Petterson N, Liu J, In t Zandt R, Carvalho C, Orbom A, et al.
Front Med (Lausanne)
. 2024 Apr;
11:1276420.
PMID: 38654839
Methods: C57BL/6 mice received bleomycin (i.p. 35iU/kg) or saline as control twice per week for 4 weeks. Mice were monitored until 2 weeks after cessation of bleomycin administration (w4 + ...
6.
B Wrammerfors E, Tornquist E, Pierantoni M, Sjogren A, Tengattini A, Kaestner A, et al.
Osteoarthritis Cartilage
. 2024 Mar;
32(6):702-712.
PMID: 38447631
Objective: To investigate the feasibility of using neutron tomography to gain new knowledge of human articular cartilage degeneration in osteoarthritis (OA). Different sample preparation techniques were evaluated to identify maximum...
7.
Palbrink A, In t Zandt R, Magnusson M, Degerman E
Acta Otolaryngol
. 2023 Feb;
143(2):127-133.
PMID: 36735299
Background: Diabetes is associated with inner ear dysfunction. Furthermore, C57BL/6J mice fed high fat diet (HFD), a model for insulin resistance and diabetes, develop endolymphatic hydrops (EH). Aim: Evaluate if...
8.
Mahmutovic Persson I, Fransen Pettersson N, Liu J, Falk Hakansson H, Orbom A, In t Zandt R, et al.
J Clin Med
. 2020 Nov;
9(11).
PMID: 33218212
Non-invasive imaging biomarkers (IBs) are warranted to enable improved diagnostics and follow-up monitoring of interstitial lung disease (ILD) including drug-induced ILD (DIILD). Of special interest are IB, which can characterize...
9.
Palbrink A, Kopietz F, Moren B, In t Zandt R, Kalinec F, Stenkula K, et al.
BMJ Open Diabetes Res Care
. 2020 Apr;
8(1).
PMID: 32238362
Objective: The mechanisms underlying the association between diabetes and inner ear dysfunction are not known yet. The aim of the present study is to evaluate the impact of obesity/insulin resistance...
10.
Degerman E, In t Zandt R, Palbrink A, Magnusson M
Acta Otolaryngol
. 2019 May;
139(8):685-691.
PMID: 31145014
The exact pathophysiological mechanism(s) underlying endolymphatic hydrops (EH) remain elusive. We have previously shown that chronic administration of vasopressin and inhibitors of the cAMP/cGMP degrading enzymes (PDE3, PDE4, PDE5) results...